TLX
Telix Pharmaceuticals Limited
NASDAQ · Healthcare · Biotechnology · AU
$11.92
+1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 1.2B | 783.2M | 502.5M | 160.1M |
| Cost of Revenue | 1.1B | 565.2M | 273.5M | 188.2M | 65.2M |
| Gross Profit | 1.4B | 640.2M | 509.7M | 314.4M | 94.9M |
| Operating Expenses | |||||
| R&D Expense | 513.1M | 256.8M | 121.0M | 128.8M | 57.9M |
| SG&A Expense | 639.0M | 356.8M | 207.1M | 134.2M | 87.1M |
| General & Admin Expense | 136.2M | 145.0M | 121.7M | 79.3M | 49.1M |
| Selling & Marketing Expense | 122.6M | 211.8M | 85.5M | 54.9M | 38.0M |
| Other Expenses | 132.0M | — | 99.4M | 270.0K | 41.9M |
| Total Operating Expenses | 1.3B | 613.6M | 427.5M | 263.3M | 186.9M |
| Cost and Expenses | 2.4B | 1.2B | 701.1M | 486.7M | 252.0M |
| Operating Income (EBIT) | 74.1M | 26.6M | 82.1M | 15.8M | (91.9M) |
| Non-Operating | |||||
| Interest Income | 16.9M | 8.7M | 10.9M | 671.0K | 1.0K |
| Interest Expense | 39.2M | 55.1M | 21.5M | 8.9M | 406.0K |
| Net Interest Income | (22.3M) | (46.3M) | (10.6M) | (8.3M) | (405.0K) |
| Other Non-Op Income/Expense | 7.2M | (34.5M) | (26.1M) | (12.8M) | (6.7M) |
| Non-Operating Income (excl Interest) | 6.3M | (20.5M) | (10.4M) | 35.7M | 12.1M |
| EBT (Pre-Tax Income) | 81.3M | (7.9M) | 56.1M | 3.1M | (98.6M) |
| Income Tax Expense | (1.7M) | 2.8M | 6.1M | (2.1M) | 5.5M |
| Bottom Line | |||||
| Net Income | 83.0M | (10.7M) | 49.9M | 5.2M | (104.1M) |
| Earnings from Cont. Ops | 83.0M | (10.7M) | 49.9M | 5.1M | (104.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 83.0M | (10.7M) | 49.9M | 5.2M | (104.1M) |
| Per Share | |||||
| Basic EPS | $0.25 | ($0.03) | $0.15 | $0.02 | ($0.34) |
| Diluted EPS | $0.24 | ($0.03) | $0.14 | $0.02 | ($0.34) |
| Revenue Per Share | $7.37 | $3.57 | $2.36 | $1.57 | $0.52 |
| Shares | |||||
| Basic Shares Outstanding | 339.2M | 337.9M | 331.2M | 319.2M | 310.6M |
| Diluted Shares Outstanding | 356.9M | 337.9M | 345.2M | 323.7M | 310.6M |
| Profitability Metrics | |||||
| EBITDA | 137.9M | 79.8M | 98.2M | 23.0M | (92.8M) |
| D&A | 70.1M | 32.7M | 5.7M | 6.7M | 5.4M |
| EBIT | 67.8M | 47.2M | 92.5M | 16.2M | (98.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026